HC Wainwright Comments on Omeros' Q2 Earnings (NASDAQ:OMER)

Omeros Co. (NASDAQ:OMER - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Omeros in a research report issued to clients and investors on Tuesday, June 10th. HC Wainwright analyst B. Folkes forecasts that the biopharmaceutical company will post earnings of ($0.39) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Omeros' current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros' Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.27) EPS and FY2026 earnings at ($1.14) EPS.

Several other research analysts have also issued reports on the company. Wall Street Zen lowered Omeros from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. D. Boral Capital reaffirmed a "buy" rating and issued a $36.00 price target on shares of Omeros in a report on Tuesday, May 13th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Friday, May 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Omeros presently has an average rating of "Moderate Buy" and an average target price of $18.00.

Omeros Trading Down 4.2%

Omeros stock traded down $0.15 during trading on Wednesday, reaching $3.40. The company had a trading volume of 696,461 shares, compared to its average volume of 689,598. The firm's 50-day simple moving average is $5.11 and its 200 day simple moving average is $7.74. The firm has a market capitalization of $199.22 million, a price-to-earnings ratio of -1.47 and a beta of 2.20. Omeros has a 52 week low of $2.97 and a 52 week high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OMER. Raymond James Financial Inc. bought a new position in shares of Omeros in the 4th quarter worth about $124,000. Price T Rowe Associates Inc. MD grew its stake in shares of Omeros by 12.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company's stock worth $392,000 after purchasing an additional 4,401 shares during the last quarter. Cerity Partners LLC boosted its holdings in shares of Omeros by 9.9% in the fourth quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock worth $286,000 after buying an additional 2,600 shares during the period. Quantbot Technologies LP acquired a new position in shares of Omeros in the fourth quarter worth about $46,000. Finally, Deutsche Bank AG boosted its holdings in shares of Omeros by 38.2% during the fourth quarter. Deutsche Bank AG now owns 40,046 shares of the biopharmaceutical company's stock worth $396,000 after purchasing an additional 11,068 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.